Designing Longevity
Skip to main content
Moderate EvidencePeptide

Setmelanotide

The Imcivree molecule

Melanocortin-4 receptor agonist

Last updated: November 2026
Share:

Setmelanotide is a peptide medicine sold as Imcivree. It acts on the -4 receptor, which helps regulate hunger and body weight. The FDA approves it for certain people with acquired hypothalamic obesity, Bardet-Biedl syndrome, or specific genetic deficiencies. These are distinct diagnoses. Its approval and trial results do not establish a benefit for general obesity.

Evidence Level: Moderate Evidence

Some human data, strong animal studies, plausible mechanism

Regulatory Status: FDA-approved as Imcivree for specific ages and causes of obesity, including acquired hypothalamic obesity, Bardet-Biedl syndrome, and qualifying POMC, PCSK1, or LEPR deficiency. This approval applies to the labeled product and uses.

How It Works

Setmelanotide activates the -4 receptor, which is part of a pathway that helps regulate hunger and energy balance. Some rare genetic conditions disrupt signals in this pathway. Acquired hypothalamic obesity follows injury or dysfunction of the hypothalamus, such as after a tumor or its treatment.

The FDA label identifies who may be considered for Imcivree. The cause of obesity and the person’s age matter. For POMC, PCSK1, or LEPR deficiency, the label also specifies how genetic test results are interpreted. A clinician must assess whether the diagnosis matches the label. See the linked Imcivree care guide for the practical questions.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Weight lossModerate certainty

Setmelanotide reduced BMI compared with placebo after 52 weeks of treatment in people with acquired hypothalamic obesity.

Population: People aged 4 years and older with acquired hypothalamic obesity who met trial criteria

Why this rating

A direct, trial supports the outcome for this diagnosis. The study was sponsor funded, and the paper and FDA label describe different analysis populations. Neither supports generalizing to other causes of obesity.

GRADE downgrade factors applied

  • Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).

Supporting studies

Reviewed November 2026How we grade
Weight lossLow certainty

Setmelanotide reduced BMI compared with placebo during the randomized period in the studied Bardet-Biedl syndrome population.

Population: People aged 6 years and older with obesity and a clinical Bardet-Biedl syndrome diagnosis in the pivotal study

Why this rating

The short randomized phase supports a diagnosis-specific BMI effect. The longer follow-up used treatment and a small cohort. The current FDA label extends to age 2 and older using additional pediatric evidence, so this one study does not cover every labeled age.

GRADE downgrade factors applied

  • Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.

Supporting studies

Reviewed November 2026How we grade
Weight lossLow certainty

Weight reduction was observed during setmelanotide treatment in separate studies of POMC and LEPR deficiency.

Population: People with qualifying POMC or LEPR deficiency enrolled in small single-arm studies

Why this rating

The studies measured a direct outcome in the relevant diagnoses but lacked a randomized comparator and enrolled few people. Do not transfer their result to PCSK1 deficiency, all genetic syndromes, or general obesity.

GRADE downgrade factors applied

  • Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
  • Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.

Supporting studies

Reviewed November 2026How we grade

Potential Benefits

  • In a randomized trial involving people with acquired hypothalamic obesity, BMI decreased more with setmelanotide than with placebo after 52 weeks of treatment. This result applies to that diagnosis.
  • A smaller Bardet-Biedl syndrome trial reported BMI reductions during its randomized phase and longer treatment. The longer period had a different comparison design.
  • Separate small single-arm trials in POMC and LEPR deficiency reported weight reductions. Those results answer narrower genetic-diagnosis questions.

Risks & Considerations

  • The current label warns about depression and suicidal thoughts, serious allergic reactions, skin darkening and changes in moles, and sexual adverse reactions.
  • For acquired hypothalamic obesity, the label adds monitoring for acute adrenal insufficiency and, in people with central diabetes insipidus, sodium imbalance.
  • The approved uses and ages are specific. A familiar product name alone does not establish that an individual meets the labeled criteria.

Practical Tips

  • 1Ask a clinician familiar with the relevant diagnosis what records establish the cause of obesity and whether the current Imcivree label fits.
  • 2For POMC, PCSK1, or LEPR deficiency, ask how the actual genetic result is interpreted in the clinical context.
  • 3Ask the care team about the labeled monitoring, pharmacy route, insurance requirements, and full cost before making a treatment decision.

Key Research

Setmelanotide for the Treatment of Acquired Hypothalamic Obesity

New England Journal of Medicine, 2026

A 52-week randomized trial found a greater reduction in BMI with setmelanotide than placebo in participants with acquired hypothalamic obesity. The journal report and current FDA label describe different analysis populations, so figures from them should retain their own source and denominator.

View Study

Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome

The Lancet Diabetes & Endocrinology, 2022

The trial included a 14-week randomized comparison followed by an treatment period. The FDA approval is for Bardet-Biedl syndrome, not every condition studied in the trial.

View Study

Efficacy and safety of setmelanotide in individuals with severe obesity due to LEPR or POMC deficiency

The Lancet Diabetes & Endocrinology, 2020

Separate, small, single-arm studies observed weight reduction in people with specific genetic deficiencies. They did not directly compare setmelanotide with another medicine or placebo.

View Study

Sources and regulatory records

Frequently Asked Questions

What is setmelanotide?

It is a peptide medicine that acts on the -4 receptor. Imcivree is its FDA-approved branded product for certain specific causes of obesity.

Is Imcivree for ordinary weight loss?

The FDA label limits Imcivree to acquired hypothalamic obesity, Bardet-Biedl syndrome, and qualifying POMC, PCSK1, or LEPR deficiency. It does not include general obesity.

How is it different from a GLP-1?

Setmelanotide acts on the -4 receptor, while medicines act on the GLP-1 receptor. They have different labeled uses and study populations. Trial results across those populations cannot be used as a simple head-to-head ranking.

What should I ask about access?

Ask a clinician to confirm the diagnosis and labeled use, then ask the care team or health plan about the exact prescription, dispensing route, coverage requirements, monitoring, and full cost.

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated November 2026.

Found this helpful? Share it or save it for later.

Share:

See a problem or outdated information? Tell us.